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Abstract
Background: The knowledge on type specificity and factors that increase or decrease the risk of incident HPV-
infections is important to better understand the dynamics of HPV-infections.
Methods: A series of 329 pregnant women were enrolled in Finnish Family HPV Study at 3
rd trimester of
pregnancy and followed-up for 6 years, during which 203 baseline HPV-negative women acquired incident HPV
infection. Incidence times and incidence rates (IR) were calculated for 24 low-and high-risk HPV-types detected by
Multiplex-HPV-genotyping at each visit. Poison regression was used to estimate predictors of incident HPV
infections of species 7 and 9 HPV-genotypes.
Results: HPV16 was the most frequent (47.8%) incident genotype followed by multiple-type infections (25.1%), and
single infection with HPV18, 70, 6 and 45. Actuarial mean times to incident event were longest for HPV31 (34.5
months) and HPV45 (32.8 months), while crude mean times were longest for HPV56 (42.4 months) and HPV16 (23.1
months). Actuarial IR was highest for HPV16 and multiple-type infections. Independent protective factors against
incident infections were 1) > 2 life-time sexual partners (p = 0.014), 2) later initiation of oral contraceptives (age >
20 years) (p = 0.017) and 3) pregnancy at FU visit (p = 0.0001).
Conclusions: Among newly delivered mothers, higher number of life-time sexual partners, initiation of OC use
after age 20 and becoming pregnant during FU decreased the risk for incident species 7/9 HPV infections.
Background
Human papillomavirus (HPV)-types that infect the female
genital tract belong to the alpha-papillomavirus-genus
which includes 15 species and 58 HPV-genotypes. Accord-
ing to their clinical behavior, 15 HPV-types are high-risk
(HR)-types, 12 are low-risks (LR)-HPV-types, and three
probable HR-types [1,2]. Worldwide, the eight most com-
mon HPV-types in cervical cancer are all included either
into species7 (HPV18,45) or 9 (HPV16,31,33,35,52,58) [3].
The studies on incident HPV-infections have been evaluat-
ing HR- and LR-types collectively or HPV in general [4-7]
or acquisition of incident HPV-infections have been
assessed at genotype level [8-16].
Among young women, incident infections with HR-
HPV-types especially with HPV16 [8-11,14-16] seem to be
more common than LR-types [9,17]. The knowledge on
type specificity and factors that increase or decrease the
risk of incident HPV-infections is important to better
understand the dynamics of HPV-infections and to take
appropriate measures for their optimal prevention.
The aim of this study was to assess the frequency of
type-specific incident HPV-infections in addition to
actuarial and crude incidence-times and -rates of the most
common LR- and HR-HPV- genotypes in newly delivered
mothers, prospectively followed-up for 6 years in
the Finnish Family HPV Study. Risk-factors of incident
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Methods
Subjects
The Finnish Family HPV Study is a prospective cohort
study conducted at the Department of Obstetrics and
Gynecology, Turku University Hospital and the Institute
of Dentistry, Faculty of Medicine, University of Turku.
The study was designed to evaluate the dynamics of HPV
infections in mothers, fathers and their newborn infants. A
total of 329 women, 131 men and 331 children were
recruited to this study between 1998 and 2002. An
extended 6 years follow-up was performed between 2006
and 2008, and invitation to this follow-up visit was send to
all women and men in this cohort; a total of 171 women
and 44 men was finally reached and examined.
Subjects in this cohort comprise mothers-to-be who
were recruited at the minimum of 36 weeks of pregnancy
[18] and followed-up for up to 6 years (Mean = 54.9
months, SD = 27.3, Median = 62.4; range: 1.6-94.5
months) after the delivery. The Research Ethics Commit-
tee of Turku University Central Hospital has approved the
study protocol and its amendment (#2/1998 and #2/2006)
and an informed consent have been gained from all the
participants of this study. Altogether, 329 mothers were
recruited (mean age 25.5 years, SD = 3.6 years), of whom
203 baseline HPV-negative women (mean age 25.48 years,
SD = 3.1 years, range 18-38) who developed an incident
event during the follow-up (FU) were included in this
study. The women of this study are of Caucasian origin,
have the same ethnic background and are representative
of the Finnish population. The flowchart of the study set-
ting is described in Figure 1. Some of the study partici-
pants were lost to follow-up, mainly due to difficulties in
getting to study appointments or lack of child care. Struc-
tured questionnaire for recording demographic data and
potential risk factors (i.e. sexual behavior, gynecological
and obstetric history and risk factors for HPV infections)
were recorded at the 2-month and 6-year FU-visits. Dur-
ing the 12-month and 36-month FU-visit, the data on the
presence of HPV-induced clinical lesions, such as oral
papilloma, skin and genital warts were recorded. Selected
data from these records were used for risk assessment in
the present study, as separately indicated.
Samples
The scrapings for HPV-testing were taken at the base-
line and at 2-,12-,24-,36-month and 6-year FU-visits.
Sampling was done with a cytobrush from the uterine
cervix (Cytobrush, MedScand, Malmö, Sweden) using
sampling media of 0.05 M phosphate-buffered saline
with 100 μg gentamycin. The samples were immediately
frozen at -20°C and stored at -70°C. Scrapings from the
oral mucosa were also collected at each visit [19], but
only the baseline DNA data were used in the present
study.
Pap smears
A routine pap smear was taken from all women at base-
line, and 2-,12-,24- and 36-month, by using conven-
tional three-sample technique with wooden spatula and
cytobrush (Medscand, Malmö, Sweden) as described
earlier [18].
HPV-genotyping
The HPV genotyping was done by multiplex-HPV-geno-
typing kit (Multimetrix, Progen Biotechnik GmbH, Hei-
delberg, Germany) as outlined in our recent study [20].
Figure 1 Flow chart of the mothers included in the Finnish
Family HPV study.
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genotypes: LR-HPV: 6,11,42,43,44,70; HR-HPV: 16,18,26,
31,33,35,39,45,51,52,53,56,58,59,66,68,73,82 [21]. With
Luminex LX-100-analyzer (Bio-Plex 200 System, Bio-
Rad Laboratories, Hercules, USA) medium fluorescence
intensity (MFI) of at least 100 beads was computed for
each bead set in the sample. The cut-off value for each
run and HPV-type was 1,5x background MFI (negative
control)+5MFI.
HPV genotyping was done using the earlier PCR pro-
duct which was now re-amplified with GP05+ and bio-
GP06+-primers [22]. Originally DNA was extracted
from scrapings with high salt method [23]. The PCR
products were then hybridized with digoxigenin-labelled
HR-HPV oligoprobe cocktail (HPV-types 16,18,31,
33,35,39,45,51,52,54, 56 and 58) to detect the presence
of any high risk HPVs [24].
As HPV16 is the most prevalent genotype, we retested
all HPV16-positive samples as described by Schmidt and
co-workers [21] and discounted the possibility of false
positive samples due to contamination.
Serology
Blood samples were taken at baseline and at 2-,12-,24-
and 36-month and 6 years of FU. Samples were analysed
for the antibodies to the major capsid protein L1 of
HPV types 6,11,16,18 and 45, and were analysed by
multiplex HPV serology based on glutathione S-transfer-
ase fusion-protein capture on fluorescent beads. These
results were interpreted using the technique and cut-off
values as recently described [25]. The Selected data
from these records were used for risk assessment in the
present study (Table 1).
Statistical analyses
All statistical analyses were run using SPSS
® (SPSS, Inc.,
Chicago, USA) and STATA (Stata Corp., College Station,
TX, USA) software packages (PASW Statistics for Win-
dows, version 18.0.1 and STATA/SE 11.0). Frequency
tables were analyzed using the c
2-test, with the likelihood
ratio or Fisher’s exact test for categorical variables. Differ-
ences in the means of continuous variables were analyzed
using non-parametric (Mann-Whitney or Kruskal-Wallis)
tests for two- and multiple independent samples,
respectively.
Outcomes of HPV-infection and type-specific incident
infection
The genotype-specific outcomes in each woman were
assessed by comparing the viral events at each FU visit to
the baseline HPV status and are presented in Figure 2.
The following 6 different outcome patterns were defined:
1)always negative, 2)incident HPV, 3)type-specific persis-
tence, 4)non type-specific persistence, 5)fluctuation, and 6)
clearance (= transient). The present study focused on
those 203 baseline-negative women who developed an
incident HPV-infection during the FU (outcome 2) (=
women who were HPV-negative at baseline and acquired
incident HPV infection during the FU). Genotype-specific
persistence denoted for any case with two (or more) con-
secutive FU-samples positive for the same individual geno-
type as a single infection or as a part of multiple-type
infection. Non-genotype specific persistence includes all
cases with two (or more) consecutive samples positive for
different HPV genotypes. Clearance was defined as an
event (at any FU visit) when a previously HPV-positive
test turned out to be negative and remained HPV-negative
until the end the FU. Fluctuation is a pattern where conse-
cutive samples are intermittently HPV+ and HPV- with
different HPV genotypes, without any two consecutive
samples positive for the same or different viral genotype.
Times in months to incident infections were calculated
from baseline visit to the first incident event separately for
actuarial and crude times. To calculate the former, all
baseline HPV-negative women (n = 255) were included in
Kaplan-Meier analysis, cases being censored at the first
incident event (those who had) or at the end of FU (those
who did not develop incident event). Only those women
who had completed at least two FU visits were included to
this study. To calculate the crude incidence times, only
those women with an incident infection with an individual
genotype (or species) were included. Both actuarial and
crude incidence rates (IR) were calculated, and expressed
per 1000 women months at risk (wmr). To get genotype-
specific actuarial IRs, the number of incident events for
each individual genotypes (and species) was divided by the
total wmr (6,212 months for all baseline HPV-negative
women), including also the women with no incident event.
To calculate crude IRs, only the women with incident
events were included and the number of incident events
for each individual genotype (or species) was divided by
the wmr of those women only. To compare the individual
IRs, the rate ratio statistics (STATA) was used, with test-
specific 95% confidence intervals (95%CI).
Predictors of type-specific incident HPV-infections
To analyze the predictors of incident HPV-infections,
we used the species-specific incident infection approach
to avoid stratifying the material into individual geno-
types with single or few cases only. Furthermore, we
were only interested in incident HPV-infections by the
key HR-HPV-types, i.e., those of Species 7 and Species
9. Women that had an incident infection recorded by a
type or types from species 7 and/or 9 were included to
these analyses (n = 133).
Poisson regression analysis was used for panel data,
clustered by mother-ID and executed (in univariate and
multivariate-mode) using population-averaged (PA)
Louvanto et al. BMC Infectious Diseases 2011, 11:179
http://www.biomedcentral.com/1471-2334/11/179
Page 3 of 11Table 1 Predictors of species 7 and 9-type specific incident
a HPV infections
b
Covariates Incident Species 7 and 9 HPV Infections
Crude IRR 95% CI P @Adjusted IRR 95% CI P
Age (at study entry; continuous var) 0.98 0.96-1.02 0.090 0.99 0.98-1.01 0.678
Mother seroconverted to HR-HPV
No Ref
Yes 0.81 0.67-0.98 0.039 0.84 0.69-1.03 0.106
Mother seropositive to HR-HPV at baseline
Yes Ref
No 1.10 0.85-1.42 0.463
Baseline oral HR-HPV DNA status
HR-HPV- Ref
HR-HPV+ 0.80 0.54-1.19 0.285
Baseline PAP smear
ASCUS+ Ref
Negative (WNL) 1.76 0.76-4.10 0.184
Marital Status at baseline
Singe Ref
Married 1.19 0.77-1.81 0.419
Living with partner 1.30 0.86-1.97 0.208
Divorced 1.42 0.95-2.15 0.086
Employment status
Employed Ref
Student 0.82 0.61-1.10 0.192
Unemployed 0.90 0.75-1.07 0.257
Age at onset of sexual activity
Below 13 years Ref
Above 13 years 1.15 1.05-1.27 0.003 1.05 0.93-1.17 0.394
No. of sexual partners until age of 20 yrs
0-2 partners Ref
3-5 partners 0.89 0.76-1.05 0.201
6-10 partners 1.05 0.92-1.19 0.410
> 10 partners 0.73 0.46-1.18 0.206
Life-time number of sexual partners
1-2 partners Ref
3-5 partners 1.12 1.02-1.24 0.015 1.12 1.02-1.23 0.011
6-10 partners 0.83 0.61-1.13 0.246 0.85 0.62-1.16 0.311
> 10 partners 0.81 0.63-1.04 0.105 0.81 0.63-1.04 0.104
No. of weekly intercourse
0-1 intercourse Ref
2-4 intercourses NC
5-10 intercourses NC
> 10 intercourses NC
> 10 vs. 0-1 (only calculable) 1.03 0.88-1.14 0.961
No. of deliveries in all partnerships (continuous var)* 1.06 0.98-1.15 0.107
Practices of oral sex
No Ref
Yes 1.02 0.87-1.20 0.739
Practices of anal sex
No Ref
Yes 1.22 0.97-1.55 0.087 1.16 0.83-1.62 0.375
Initiation of OC usage
Above 20 years Ref
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a HPV infections
b (Continued)
Below 20 years 1.32 1.04-1.23 0.004 1.13 1.02-1.26 0.017
OC use (Y/N)
Never use Ref
Ever use 1.01 0.74-1.37 0.948
Smoking habits
Never smoker Ref
Ever smoker 1.06 0.92-1.21 0.384
Initiation of smoking
10-13 years of age
> 13 years of age 1.16 1.01-1.35 0.028 1.11 0.95-1.31 0.159
History of STD
Yes Ref
No 1.06 0.89-1.27 0.505
History of genital warts
No Ref
Yes 0.93 0.81-1.08 0.372
History of oral warts
Yes Ref
No 1.08 0.79-1.32 0.823
2nd pregnancy during FU
No 2
nd pregnancy during FU Ref
Yes, 2
nd pregnancy during FU 0.29 0.16-0.55 0.0001 0.32 0.17-0.61 0.0001
Change in marital status during FU*
No Ref
Yes; living with partner 0.74 0.41-1.32 0.315 0.78 0.48-1.28 0.340
Yes, married 1.04 0.89-1.22 0.572 1.10 0.84-1.45 0.474
Yes, divorced 1.11 1.01-1.22 0.019 1.16 0.97-1.40 0.102
No. of current sexual partners*
No Ref
1 or more 1.02 1.00-1.04 0.027 **
Species 7 HPV genotypes: 18,39,45,59,68,70,85; Species 9 HPV genotypes: 16,31,33,35,52,58,67;
aCount outcome (incident events/person time at risk), as defined
by the first incident event in baseline HPV-negative women during the follow-up;
bResults obtained from panel Poisson regression for count outcomes (log-link),
clustered by woman-ID, FU visits as time variable, and 95%CI calculated by robust variance estimation; @adjusted for age and all significant univariates in the
model; *the variables that are from the FU questionnaire; NC; no convergence obtained (with any working correlation structure) WNL, within normal limits;
**rejected because of collinearity
Figure 2 Outcome of the HPV infections during follow-up*. *The genotype-specific outcome of HPV infection in each woman was assessed
by comparing the viral events at each FU visit to the baseline HPV status, and 6 different main outcomes were identified. This study evaluated
the incidence of genotype-specific HPV infection, women in the second outcome.
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panel settings, and incident HPV-infection (count vari-
able) as the dependent variable, with Poisson log-link
function. The independent within-group correlation
structure for PA model, with robust variance estimator
(of 95%CI) to account for within-subject correlation was
the best-fitted covariance pattern, defined by QIC
(quasi-likelihood information criterion [27]. With these
options, Poisson regression for panel data is similar to
PA GEE-model, both giving identical results.
In univariate Poisson, we first tested all covariates
recorded at baseline questionnaire as well as some
selected variables from the FU questionnaire (e.g. a new
partner), previously implicated as potential risk factors
of HPV in this cohort [18,28]. In the final multivariate
model, only variables (as entities, not as sub-categories)
that were significant (or borderline significant) in uni-
variate Poisson were entered and were adjusted for age
at study entry. All statistical tests were two-sided and
declared significant at p-value < 0.05 level.
Results
Type-specific incident infections
Of the 255 baseline HPV-negative mothers enrolled in
the cohort, 203 experienced an incident event during
the FU. The mean follow-up time of these 203 mothers
was 58.6 ± 25.2 (SD) months (median 64.3; range 6-
94.5). HPV16 caused most frequently incident infection
(47.8%, n = 97), followed by HPV18 (3.9%, n = 8),
HPV70 (3.0%, n = 6), HPV6 and HPV45 (both 2.5%, n =
5). Multiple-type infections were the second most com-
mon incident events after HPV16, with 25.1% (n = 51)
frequency. HPV16 and HPV18 were detected in 70.6%
(n = 36) and 27.2% (n = 14) of the multiple-type infec-
tions, respectively.
The mean times to the first incident event are shown
in Table 2. The longest actuarial mean time (75 months)
was associated with a single case of HPV33. Of the types
with more than one case, HPV31 and HPV45 had
actuarial mean times of 34.5 months and 32.8 months,
respectively, while the actuarial mean times of HPV-
types 6,16,18,35,56,58 varied between 21.5-29 months.
Apart from the single case of HPV33, HPV56 showed
the second longest crude mean time of 42.4 months, fol-
lowed by HPV16, 18 and 31, with 23.1, 20.6 and 20.1
months, respectively. Remaining genotypes had crude
mean times between 6.3 and 17 months.
Species 9 was the most dominant species covering
54.7% (n = 111) of all incident infections and had
actuarial mean time of 27.5 months (95%CI23.3-31.7)
and crude mean time of 22.6 months (95%CI19.7-25.4).
The second and third most common species were spe-
cies 7 and species 10, with 10.8% (n = 22) and 3.9%
(n = 8) prevalence, respectively. Actuarial mean time for
species 7, 9 and 10 was similar, 27.5, 27.5 and 27.0
months, respectively. Species 6 and 9 had the longest
crude mean incidence times, 25.0 and 22.6 months,
respectively.
The cumulative incidence of species 7 and 9 was com-
pared with species 10 in univariate survival (Kaplan-
Meier) analysis (Figure 3). Despite a lower cumulative inci-
dence rate for species 10 (benign types), the difference was
not statistically significant when compared to species 7
and 9 (log-rank test; p = 0.892).
Incidence rates
Of single genotypes, HPV16 had by far the highest
actuarial IR, 15.6/1000 wmr (95%CI12.5-18.6), followed
by multiple-type infections, with 8.2/1000 wmr (95%
CI5.96-10.45). Actuarial IR for HPV18 was markedly
lower, 1.3/1000 wmr (95%CI0.39-2.17). Due to the
dominant role of HPV16, species 9 showed the highest
IR of 17.9/1000 wmr (95%CI14.6-21.2), far exceeding
that (3.4/1000 wmr) of species 7 (Table 2).
The highest crude IR was ascribed to HPV70, accumu-
lating incident events at a rate of 157.8/1000 wmr. This
was followed by HPV73, HPV66, HPV82 and HPV52,
with IRs of 133.3/1000 wmr, 133.1/1000 wmr, 107.1/1000
wmr and 107.1/1000 wmr, respectively. The crude IRs of
HPV16 and HPV18 were far lower, and practically identi-
cal to each other, 43.3/1000 wmr and 43.4/1000 wmr,
respectively. Due to this wide variation among individual
types included in different species, the crude IRs between
the HPV-species showed much less variation, i.e., from
40/1000 wmr to 91/1000 wmr, when species 11 (HPV73
alone) is excluded (Table 2).
Predictors of species-specific incident infections
The predictors of genotype-specific incident infections
of species 7 and 9 are shown in Table 1. In univariate
Poisson regression, seven variables in total were signifi-
cantly associated with incident infection. The following
four variables were associated with increased risk: 1)
mother being seroconverted to HR-HPV during FU, 2)
< 13 years of age at onset of sexual activity, 3) 1-2 life-
time sexual partners 4) ≥2 sexual partners during FU.
The other three variables were associated with a
decreased risk of incident infection: 5) later initiation of
oral contraceptives (OC)(age > 20 years), 6) age at initia-
tion of smoking (age10-13 years) and 6) pregnancy at
FU-visit.
When all significant and borderline significant vari-
ables were entered in the multivariate Poisson PA
model, together with mother’s age, three variables
retained their significance as independent factors with
lower risk for incident species 7 and 9 infection during
the FU: 1) > 2 life-time sexual partners (p = 0.011), 2)
late (> 20 years) initiation of OCs (p = 0.017), and 3)
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estimates in sub-categories shown in Table 1.
Discussion
This is one of the first studies to assess type-specific
incident HPV-infection [8-16], in contrast to the pre-
vious studies, where acquisition of HPV-infection has
been analysed collectively for all HPV-types or acquisi-
tion of HR- and LR-types has been compared [4-7].
Similarly, in currently available literature, it is hard to
find the times to the first incidence infections at the
genotype-level, most reports being focused on duration
of incident infections [8,9,16].
We previously analysed crude incidence times collec-
tively for 13 HR-HPV-types detected by Hybrid capture
2-assay [6]. It took an average of 16.6 months to develop
the first incident HR-HPV event. In the present study,
we went further and provide these times for individual
HPV-genotypes (and species) both as actuarial and
crude format. To calculate the former, included are also
Table 2 Times to incident infections and incidence rates for different HPV genotypes and species
a
Incident
Infections
Mean Time to 1
st Incident Infection
(months)
Incident Rate (IR) per 1,000 women months at
risk (wmr)
HPV Genotype: N % Actuarial
b (95%CI) Crude
c (95%CI) Actuarial
b (95%CI) Crude
c (95%CI)
HPV6 5 2.5 27.2 (9.2-45.2) 15.2(10.1-20.2) 0.8 (0.09-1.51) 65.9 (10.0-121.5)
HPV11 2 1.0 12.8 (12.2-13.4) 12.8(12.2-13.4) 0.3 (0.01-0.76) 78.2 (2.5-179.3)
HPV16 97 47.8 25.2 (22.0-28.3) 23.1(20.2-26.0) 15.6 (12.5-18.6) 43.3 (34.8-51.7)
HPV18 8 3.9 27.1 (13.8-40.3) 20.5(14.2-26.8) 1.3 (0.39-2.17) 48.7 (15.8-81.7)
HPV31 4 2.0 34.5 (7.4-61.6) 20.1(6.1-34.1) 0.6 (0.01-1.27) 49.8 (22.4-97.7)
HPV33 1 0.5 75.0 (75.0-75.0) 75.0(75.0-75.0) 0.2 (0.01-0.47) 13.3 (1.3-39.3)
HPV35 2 1.0 21.5 (7.7-35.3) 12.9(11.7-14.1) 0.3 (0.01-0.76) 76.9 (25.5-179.3)
HPV44 1 0.5 12.5 (12.5-12.5) 12.5(12.5-12.5) 0.2 (0.01-0.47) 80.0 (6.8-221.8)
HPV45 5 2.5 32.8 (13.9-51.6) 13.7(6.7-20.6) 0.8 (0.09-1.51) 72.4 (11.2-133.6)
HPV51 2 1.0 13.4 (0-35.7) 13.4(0-35.7) 0.3 (0.01-0.76) 74.1 (24.7-172.8)
HPV52 3 1.5 9.4 (2.0-16.8) 9.4(2.0-16.8) 0.5 (0.06-1.02) 107.1(7.4-221.7)
HPV56 2 1.0 25.4 (7.7-43.1) 42.4(0-101.0) 0.3 (0.01-0.76) 23.5 (8.6-55.7)
HPV58 4 2.0 29.0 (1.0-57.0) 13.5(4.1-22.8) 0.6 (0.01-1.27) 74.1 (42.2-143.9)
HPV59 3 1.5 17.0 (2.0-32.1) 17.0(1.9-32.1) 0.5 (0.06-1.02) 58.8 (5.8-123.4)
HPV66 2 1.0 7.6 (0-17.8) 7.6(0-17.8) 0.3 (0.01-0.76) 133.1 (38.2-305.0)
HPV70 6 3.0 11.2 (2.9-19.4) 6.3(2.0-10.6) 1.0 (0.19-1.73) 157.8 (41.9-273.8)
HPV73 2 1.0 7.6 (0-18.4) 7.6(0-18.4) 0.3 (0.01-0.76) 133.3 (38.7-305.3)
HPV82 3 1.5 9.4 (2.3-16.6) 9.4(2.3-16.6) 0.5 (0.06-1.02) 107.1 (74.1-221.7)
Multiple types 51 25.1 32.1 (26.2-37.9) 19.8(16.4-23.2) 8.2 (5.96-10.45) 50.5 (36.9-63.9)
HPV Species:
Species 5 (26,51,69,82) 5 2.5 11.0 (2.7-19.3) 11.0(2.7-19.3) 0.8 (0.09-1.51) 90.9 (14.9-166.9)
Species 6 (30,53,56,66) 4 2.0 16.5 (3.5-29.4) 25.0(0-56.3) 0.6 (0.01-1.27) 40.0 (1.6-78.4)
Species 7 (18,39,45,59,68,70,85) 22 10.8 27.5 (17.3-37.7) 14.6(10.5-18.7) 3.5 (2.1-5.0) 68.5 (40.9-96.2)
Species 9 (16,31,33,35,52,58,67) 111 54.7 27.5 (23.3-31.7) 22.6(19.7-25.4) 17.9 (14.6-21.2) 44.3 (36.3-52.4)
Species 10 (6,11,13,44,55,74) 8 3.9 27.0 (11.0-42.9) 14.2(11.2-17.4) 1.3 (0.39-2.17) 70.2 (23.3-117.0)
Species 11 (34,73) 2 1.0 7.6 (0-18.4) 7.6(0-18.4) 0.3 (0.01-0.76) 133.3 (38.7-305.3)
a among the 203 women of the Finnish Family HPV study who had an incident infection during the FU;
ball baseline HPV-negative women at risk, months at risk
calculated 1) until the first incident event, or 2) as total FU months for those with no incident event (Total wmr = 6,212);
conly women with an incident event
(months at risk calculated until the first incident event);
Figure 3 Cumulative incidence of species 7, 9 and 10 HPV
infections in univariate survival (Kaplan-Meier) analysis.
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incident event, while the latter is calculated only for
women who develop incident events. Thus, the actuarial
times reflect the real-life situation, while indicating how
long it takes in a cohort of baseline HPV-negative
women to develop the first incident infections. On the
other hand, the crude times indicate the time that these
first incident infections take to develop among women
who all experience an incident event. These crude (type-
specific) incidence times provide a robust measure to
compare different HPV-genotypes in their speed to
d e v e l o pt h ef i r s ti n c i d e n te v e n t s( T a b l e2 ) .I nt h i s
respect, individual genotypes showed marked differences
in their crude incidence times, varying within the range
of 2 to 90 months, with the mean of 20.3 and median of
13.5 months (data not shown). Generally speaking, LR-
HPV-types had shorter crude mean incidence times
than HR-HPV-genotypes. However, despite the signifi-
cant overall difference (p = 0.0001) between the indivi-
dual genotypes, these results are hampered by multiple
comparisons and a small number of cases in each strata.
Of interest is the observation that no significant differ-
ences were observed between mean incidence times of
HPV16, HPV18 and multiple-type infections, each being
represented by sufficient number of cases.
As evident in Figure 3, these incident events show a ten-
dency for clustering around the time points of the control
visits, i.e., at 2-, 12-, 24-, 36- months and 6 years. This flaw
is inherent to the study design, however, and equally
affects all studies with similar design, i.e., HPV sampling at
irregular (and relatively long) intervals. Because of the fact
that the incident events rarely (if ever) occur exactly at the
time point of sampling, but somewhere in between the
two subsequent samplings, and because the event leads to
censoring of the subject (= no longer at risk for incident
event), we can speak about interval censoring. Due to the
fact that there are both “left-censored and right-censored”
(relative to the point) data that occur at random, we feel
that this should not cause a major bias, however. Of
course, the exact times can only be obtained by very short
(1 to 3 months) sampling times, which in the case of HPV
(having protracted clinical course) are not feasible in
practice.
Also the IR can be calculated as actuarial and crude, as
done here. These two IRs are markedly different, because
of the significantly different person months at risk. This
also makes comparison between individual studies diffi-
cult, particularly when the FU-times and cohort size are
substantially different. If one compares a setting where
1000 women are followed-up for 10 months (10.000
wmr), and another one with 100 women followed-up for
100 months (10.000 wmr), certainly the IRs in the latter
are higher. This is because the median incidence time is
around 12-13 months and only a fraction of events can
be detected with a short FU-time. In addition, it is essen-
tial to know the age-profile of the cohort, because IR for
HPV infection is critically age-dependent [7].
In our cohort, actuarial IR was by far the highest for
HPV16, 15.6/1000 wmr. This is consistent with other stu-
dies, where HPV16 had the highest actuarial IR, albeit the
absolute IRs of these cohorts was much lower. A young
women’s health study-cohort from USA reported an
actuarial IR of 5.9/1000 wmr for HPV16 [9]. In the Lud-
wig-McGill low-income cohort, the actuarial IR for
HPV16 was 1.4/1000 wmr [8], which is very similar to
another cohort consisting of sexually active women from
Hawaii, 1.77/1000 wmr [16]. Due to the dominant role of
HPV16, also the actuarial IR of species 9 was the highest
17.9/1000 wmr, which is three times higher than recently
published by Goodman and co-workers. (5.4/1000 wmr)
[16]. As pointed out above, these differences are explained
by different cohort sizes and particularly by much shorter
FU-times of the other studies, 10-15 months only [8,9,16].
Another factor is the different age-profile; the mean age of
our cohort was 25.5 years which is close to 24.2 years in
the study by Giuliano and co-workers [9] where as the
mean age in the study by Goodman and co-workers was
35 years [16]. The IRs are higher in our cohort and Giu-
liano cohort [9] than in studies on older women [8,16],
which gives further support to close age-dependence [6,7].
This is one of the first studies on crude IRs, which
reflect the differences in the rates at which individual gen-
otypes accumulate incident events among women who
have these events. Although firm conclusions on single
genotypes are difficult because of the rarity of many indivi-
dual genotypes, it is interesting to note that the crude IR
of the key LR-HPV-types (HPV6,11), is almost twice as
high as that of the two main HR-types (HPV16,18). This
indicates that the former develop incident infections at
much higher rate, which is also shown by their signifi-
cantly shorter times to incident events (Table 2). Using
rate-ratio (RR) statistics, one cannot detect significant dif-
ferences between the different HPV-species in their crude
IRs (data not shown). Much larger cohort is needed to
establish whether such differences exist between individual
HR-HPV-genotypes. If confirmed, however, such data
would have important implications e.g. in the selection of
the most aggressive genotypes with high IRs as targets of
the primary prevention.
As to the risk-factors for incident species 7/9 infections,
seven variables were significant predictors in univariate
analysis. First of these was linked with HPV-serology [25];
mothers who failed to seroconvert to HR-HPV during the
FU were at increased risk for incident infections (Table 1).
It is well established that serological response to HPV-
infections needs several months to become detectable
[ 2 5 , 2 9 ] .T h u s ,w o m e nw h oe x p e r i e n c ea ni n c i d e n te v e n t
close to the end of FU have not enough time to become
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some evidence that seroconversion may fail with transient
and even with some persistent infections [30]. It is com-
monly believed that high levels of HPV-antibodies
detected after seroconversion will protect against a new
infection. Thus, seroconversion detected during the early
months of FU could implicate an incident event that took
place before the baseline visit, and these high antibody
levels, except for being incompatible with new incident
events, might also neutralise the virus and make these
women baseline HPV DNA-negative.
Initiation of smoking beyond 13 years of age was asso-
ciated with an increased risk of incident HPV-infection,
but lost its significance in multivariate model. Some stu-
dies have found no association between smoking and inci-
dent infection [10,16], whereas others indicating current
smoking to increase the risk [5,11,13,15]. Our recent ana-
lysis disclosed that initiation of smoking at < 13 years of
age increased the risk of type-specific persistence [31].
Because incident infections precede viral persistence, the
present data are consistent with this observation, implicat-
ing that women who start smoking later have had less
time to develop persistent infection, and consequently, are
at the phase when incident infections accumulate.
Women who started their sexual activity before 13 years
of age were found to have a lower risk for incident infec-
tions during the FU. Also this association is in line with
our recent analysis disclosing early age of sexual debut as
a risk factor for HR-HPV persistence [31]. It is likely that
women with later onset are at increased risk for incident
infections, just because those with longer sexual exposure
have already experienced infection, and either cleared or
developed a persistent infection by the time they reach
their 20s (mean age of this study cohort being 25.5 years).
The same analogy applies to life-time number of sexual
partners (also a proxy to HPV exposure), shown in this
study to be inversely related to the risk of incident infec-
tions, i.e., lower partner number was associated with an
increased risk. It seems likely that those with more part-
ners have already experienced such an event before
enrolled in the study, i.e., are baseline HPV+ and by defini-
tion, no longer at risk for incident infection by the same
HPV genotype.
T h ei n i t i a t i o no fO Cu s a g eb e f o r et h ea g eo f2 0
increased the risk for incident infection and was a signifi-
cant predictor also in the multivariate model. Previous
studies report conflicting results; current use of OCs has
been shown to increase [11] or decrease [4] the risk of
incident infection. In addition, it has been reported that
the current users of OCs were not in increased risk and
that the past users of OCs seemed to be protected, as
shown by a decrease of incident infections with the years
of OC use [16]. Contradictory to the previous finding, a
recent study stated that the risk for incident infection
increased with increasing years of OC use [13]. It is
obvious that further studies are needed to evaluate the
association of OC with incident infections.
Another significant protective predictor was the second
pregnancy during the FU (Table 1). No previous data are
available from a similar setting where newly delivered
mothers were prospectively followed-up. We have recently
shown that women committed to the second child did not
share many of the known life-style behavioural risk factors
of HPV-infection [32], and this could be the likely expla-
nation for this significant (IRR = 0.32,95%CI0.17-0.61)
protective effect of a new pregnancy against incident spe-
cies 7/9 HPV-infections in the present analysis. Some
recent data suggest that parity was protective especially
against LR-HPV-types [10]. In our cohort, increasing par-
ity did not show any such effect. However, in a large
screening study (the NIS Cohort), ever being pregnant was
an independent predictor of incident infection [6].
The main limitations of this current study are firstly
the small cohort size of the women; the total number of
incidence infections was 203. To gain more information
on genotype specific incident HPV-infections, times and
rates, and to increase the statistical power, a much lar-
ger cohort is needed. Secondly the women were all
pregnant at the time of enrolling to this study, as it is
the special strength of this study it also may be consid-
ered as a limitation because the detailed mechanism
how pregnancy and HPV infections interacts are not
that well understood.
Conclusions
Data obtained from this study indicate that the probabil-
ity of mothers, who test HPV-negative just before deliv-
ery, to contract an incident infection by species 7/9-
genotypes during the subsequent follow-up is less likely
among those who report more than 2 life-time sexual
partners at baseline, start using of OCs after age 20, and
become pregnant for the second time during the follow-
up. To the best of our knowledge, this is the first study
where actuarial and crude times to the incident events as
well as actuarial and crude IRs are evaluated at the geno-
type- and HPV-species level. Obtaining genotype-specific
data during long-term follow-up is needed for better
understanding of the natural history of genotype specific
HPV-infections, e.g. the times and rates at which each
genotype accumulates incident events. It sounds feasible
to reason that in the future, those genotypes with short-
est times to incident infections (i.e., the highest IRs),
could be the most appropriate targets for early preven-
tion, e.g. by genotype-specific multivalent HPV vaccines.
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